Get the Stockscreener App
1.23
7.52%
-0.10
After Hours:
1.28
0.05
+4.07%
Curis Inc stock is traded at $1.23, with a volume of 160.80K.
It is down -7.52% in the last 24 hours and down -58.72% over the past month.
Curis Inc is a biotechnology company that develops and commercializes innovative drugs and therapies in the immuno-oncology and precision oncology therapeutic areas. The company targets solid tumors, diffuse large B-cell lymphoma, advanced solid tumors or lymphomas, hematological cancers, and others. Its pipeline products include Fimepinostat, CA-170, CA-4948, CA-327, and Erivedge.
See More
Previous Close:
$1.33
Open:
$1.3
24h Volume:
160.80K
Relative Volume:
1.67
Market Cap:
$10.41M
Revenue:
$10.16M
Net Income/Loss:
$-47.57M
P/E Ratio:
-0.1493
EPS:
-8.24
Net Cash Flow:
$-42.73M
1W Performance:
-46.98%
1M Performance:
-58.72%
6M Performance:
-75.79%
1Y Performance:
-92.32%
1-Day Range:
$1.19
$1.4221
1-Week Range:
$1.19
$2.36
52-Week Range:
$1.19
$17.49
Curis Inc Stock (CRIS) Company Profile
Name
Curis Inc
Sector
Industry
Phone
617-503-6500
Address
128 SPRING STREET, LEXINGTON, MA
Compare CRIS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CRIS
Curis Inc
|
1.23 | 10.41M | 10.16M | -47.57M | -42.73M | -8.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
474.62 | 121.88B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
573.45 | 62.69B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
555.11 | 33.86B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
235.74 | 30.51B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
238.51 | 25.69B | 3.81B | -644.79M | -669.77M | -6.24 |
Curis Inc Stock (CRIS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-17-23 | Initiated | Truist | Buy |
| Apr-04-22 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Oct-13-21 | Initiated | Raymond James | Outperform |
| Mar-25-21 | Initiated | B. Riley Securities | Buy |
| Jul-29-20 | Initiated | Laidlaw | Buy |
| Jul-17-20 | Initiated | Cantor Fitzgerald | Overweight |
| Oct-24-17 | Initiated | Guggenheim | Buy |
| Mar-02-16 | Initiated | Sun Trust Rbsn Humphrey | Buy |
| Nov-09-15 | Reiterated | ROTH Capital | Buy |
| Aug-11-15 | Initiated | FBR Capital | Outperform |
| Jan-22-15 | Reiterated | Oppenheimer | Outperform |
| Jan-21-15 | Reiterated | ROTH Capital | Buy |
| May-09-14 | Reiterated | Oppenheimer | Outperform |
| Oct-02-13 | Initiated | Robert W. Baird | Outperform |
| Sep-30-13 | Initiated | Chardan Capital Markets | Buy |
| Nov-14-12 | Initiated | Stifel Nicolaus | Hold |
| Jan-31-12 | Reiterated | Brean Murray | Buy |
| Jan-31-12 | Reiterated | Summer Street Research | Buy |
| Dec-09-11 | Initiated | Oppenheimer | Outperform |
| Oct-06-11 | Initiated | Summer Street Research | Buy |
| Sep-22-11 | Initiated | MLV Capital | Buy |
| Mar-21-11 | Reiterated | Brean Murray | Buy |
| Feb-26-10 | Reiterated | Roth Capital | Buy |
| Jan-07-10 | Initiated | Roth Capital | Buy |
View All
Curis Inc Stock (CRIS) Latest News
HC Wainwright Forecasts Curis’ Q1 Earnings (NASDAQ:CRIS) - Defense World
Analyst Forecasts For Curis, Inc. (NASDAQ:CRIS) Are Surging Higher - Yahoo Finance
Curis targets accelerated approval for emavusertib in PCNSL with 12-18 month enrollment timeline - MSN
Curis to Present at Upcoming Healthcare Conference in April 2025 - BioSpace
Curis Spotlights Game-Changing IRAK4 Cancer Drug: CEO Details Development Pipeline - Stock Titan
12 Health Care Stocks Moving In Wednesday's Pre-Market Session - Benzinga
Analysts Just Published A Bright New Outlook For Curis, Inc.'s (NASDAQ:CRIS) - simplywall.st
Curis stock price target cut to $16 by H.C. Wainwright - Investing.com Australia
Curis stock plunges to 52-week low at $1.97 amid market challenges - Investing.com
Curis, Inc. (NASDAQ:CRIS) Just Reported Full-Year Earnings And Analysts Are Lifting Their Estimates - Yahoo Finance
Curis, Inc. (NASDAQ:CRIS) Q4 2024 Earnings Call Transcript - Insider Monkey
Investors Don't See Light At End Of Curis, Inc.'s (NASDAQ:CRIS) Tunnel And Push Stock Down 30% - simplywall.st
Curis: Q4 Earnings Snapshot - CT Insider
Curis Inc (CRIS) Q4 2024 Earnings Call Highlights: Financial Improvements and Promising ... - Yahoo Finance
Curis stock plunges to 52-week low at $1.97 amid market challenges By Investing.com - Investing.com South Africa
Curis (NASDAQ:CRIS) Price Target Lowered to $16.00 at HC Wainwright - Defense World
Curis Inc. Reports Q4 2024 Progress and Financials - TipRanks
Curis Inc. Earnings Call: Progress Amidst Challenges - TipRanks
Curis eyes accelerated approval for cancer drug emavusertib By Investing.com - Investing.com South Africa
Earnings call transcript: Curis Q4 2024 reveals reduced losses - Investing.com India
Curis Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Earnings call transcript: Curis Q4 2024 reveals reduced losses By Investing.com - Investing.com UK
Curis eyes accelerated approval for cancer drug emavusertib - Investing.com India
Curis Provides Fourth Quarter 2024 Business Update - PR Newswire
Curis Full Year 2024 Earnings: Revenues Beat Expectations, EPS In Line - Yahoo Finance
Curis (NASDAQ:CRIS) Coverage Initiated at StockNews.com - Defense World
Curis to Report Fourth Quarter 2024 Financial and Operating Results and Host Conference Call and Webcast on March 31, 2025 - Quantisnow
Biotech Alert: Curis Sets Date for Q4 EarningsKey Updates on IRAK4 Inhibitor Program Expected - Stock Titan
Curis Inc Entered A Purchase Agreement To Sell 2 Million Shares Of Common Stock - Marketscreener.com
Indo-Asian News Service - Indo-Asian News Service (IANS)
Curis stock hits 52-week low at $2.54 amid sharp annual decline - Investing.com Australia
Curis stock hits 52-week low at $2.54 amid sharp annual decline By Investing.com - Investing.com South Africa
StockNews.com Initiates Coverage on Curis (NASDAQ:CRIS) - Defense World
Health Care Providers To Pay Back Almost $2 Million In Medicare Fraud - Newsweek
Curis stock touches 52-week low at $2.83 amid sharp yearly decline - Investing.com Australia
Curis Inc faces potential Nasdaq delisting By Investing.com - Investing.com Australia
Curis, Inc. to Host Earnings Call - ACCESS Newswire
Curis Inc faces potential Nasdaq delisting - Investing.com
Investor Network: Curis, Inc. to Host Earnings Call - ACCESS Newswire
Curis (CRIS) Expected to Announce Quarterly Earnings on Thursday - Defense World
CURIS INC : Results of Operations and Financial Condition, Financial Statements and Exhibits (form 8-K) - Marketscreener.com
BostInnoHappy New Year! | Inno Approved Events - The Business Journals
Diddy, Jay-Z Rape Lawsuit Dropped Amid Legal Ethics Battle - Law360
CRISCuris Provides Second Quarter 2024 Financial and Operating Update - br.ADVFN.com
Curis (CRIS) Projected to Post Earnings on Thursday - Defense World
Jay-Z Sex Assault Suit Invalid Under Law, Rapper Says - Law360
Jay-Z Blasts Buzbee For 'Reputation-Destroying Allegations' - Law360
Curis Inc Stock (CRIS) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.01%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):